#China #Nanjing #IASO Bio #Cell Therapy #MediSix

IASO Biotechnology's Strategic Acquisition of MediSix Therapeutics

On August 13, 2026, IASO Biotechnology, known as IASO Bio, announced the successful completion of its acquisition of MediSix Therapeutics, a company based in Singapore that specializes in immune cell engineering and cell therapy. This significant step underscores IASO’s commitment to expanding its global reach and enhancing its capabilities in innovative cell therapies.

A Strategic Move for Global Expansion

This acquisition is a cornerstone of IASO Bio's globalization strategy. By merging MediSix's cutting-edge T-cell engineering technologies, research and development (R&D) pipeline, and a team of international talent with IASO Bio's established cell therapy, manufacturing, and commercialization proficiencies, the company aims to fortify its global R&D and operational frameworks. The integration of these capabilities will expedite the development and commercialization of groundbreaking cell therapy products on an international scale.

Founded in 2016, MediSix Therapeutics is rooted in research from Professor Dario Campana, a prominent figure in translational immunology affiliated with the Yong Loo Lin School of Medicine at the National University of Singapore. MediSix has garnered support from elite institutional investors such as ClavystBio, Lightstone Ventures, Osage University Partners, and EDBI, the investment platform managed by the Economic Development Board of Singapore. This backing has allowed MediSix to establish a formidable R&D framework and collaborate internationally.

Pioneering Technology in Cell Therapy

MediSix focuses on tackling significant challenges in cell therapy, particularly concerning T-cell malignancies. Its proprietary Protein Expression Blocker (PEBL) technology effectively inhibits unwanted protein expression on cell surfaces, decreasing fratricide among CAR-T cells. This breakthrough enables targeted treatment of antigens that are common to both T cells and target cells. MediSix's ability to combine both ex vivo and in vivo CAR-T methods sets it apart, providing exclusive technological advantages for treating a range of conditions, from hematologic malignancies to solid tumors.

The company also boasts a diverse pipeline addressing various unmet clinical needs. The flagship program, IASO107 (previously known as PCART7), is currently in clinical trials in collaboration with leading research hospitals, yielding promising efficacy and safety results thus far.

Vision and Leadership Statements

Ms. Zhang Jinhua, the Founder and CEO of IASO Bio, highlighted that this acquisition marks a pivotal point in the company's globalization efforts. She expressed confidence in MediSix's formidable scientific team and its PEBL platform, which aligns seamlessly with IASO Bio's ongoing projects. Following the acquisition, MediSix is set to advance follow-on products utilizing its innovative technology while benefiting from IASO Bio's cost efficiencies and strong execution capabilities in clinical development.

Chairman of MediSix and Managing Partner at Lightstone Ventures, Mike Carusi, echoed enthusiasm for this partnership, noting that IASO Bio’s proven operations and access to commercial resources will enhance MediSix’s clinical initiatives. He believes that the strengths of both companies will yield significant long-term benefits for the biopharmaceutical sector.

Building Future Collaborations

Additionally, KHOO Shih, CEO of ClavystBio, remarked on the complimentary strengths of MediSix and IASO Bio, emphasizing the potential for robust cross-border synergies that can accelerate the delivery of innovative therapies to patients globally.

About IASO Bio and MediSix Therapeutics

Founded in 2017, IASO Bio is among China's pioneers in commercial-stage biopharmaceutical ventures, specializing in breakthrough cell therapies targeting hematologic malignancies and autoimmune diseases. It operates a comprehensive platform that encompasses drug discovery, development, manufacturing, and commercialization activities.

The company maintains a rich and synergistic R&D pipeline featuring ten marketed and investigational products, including its leading CAR-T therapy, Equecabtagene Autoleucel Injection, which has been approved in China for treating relapsed/refractory multiple myeloma. In a similar vein, MediSix Therapeutics focuses on engineering immune cells for T-cell malignancies and autoimmune disorders, boasting a robust end-to-end R&D capability.

With this acquisition, IASO Bio and MediSix Therapeutics are poised to lead advancements in cell therapies and address pressing medical needs worldwide.